Ocera Therapeutics, Inc. (OCRX) Holdings Trimmed by VHCP Management II LLC

VHCP Management II LLC decreased its position in Ocera Therapeutics, Inc. (NASDAQ:OCRX) by 60.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 477,269 shares of the biopharmaceutical company’s stock after selling 740,603 shares during the period. Ocera Therapeutics comprises 0.2% of VHCP Management II LLC’s investment portfolio, making the stock its 20th biggest position. VHCP Management II LLC owned approximately 1.80% of Ocera Therapeutics worth $544,000 at the end of the most recent quarter.

Separately, Hikari Power Ltd increased its holdings in Ocera Therapeutics by 79.7% in the third quarter. Hikari Power Ltd now owns 676,596 shares of the biopharmaceutical company’s stock valued at $771,000 after buying an additional 300,000 shares in the last quarter. 17.69% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have weighed in on the stock. Zacks Investment Research cut shares of Ocera Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 8th. HC Wainwright cut shares of Ocera Therapeutics from a “buy” rating to a “neutral” rating and set a $1.75 price objective for the company. in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $1.69.

Shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) opened at $1.75 on Tuesday. Ocera Therapeutics, Inc. has a one year low of $0.52 and a one year high of $2.95.

Ocera Therapeutics (NASDAQ:OCRX) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, hitting analysts’ consensus estimates of ($0.24). equities analysts predict that Ocera Therapeutics, Inc. will post -0.93 earnings per share for the current year.

WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/12/05/ocera-therapeutics-inc-ocrx-holdings-trimmed-by-vhcp-management-ii-llc.html.

About Ocera Therapeutics

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Want to see what other hedge funds are holding OCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocera Therapeutics, Inc. (NASDAQ:OCRX).

Institutional Ownership by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply